Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006485 · ClinicalTrials.gov registry record · Phase 1
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 6
- Study locations
NCT02006485 is a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma that has completed, run by TG Therapeutics. The registered enrollment target is 160 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (12% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT02006485, a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
Conditions Studied
Interventions
- DRUG Ublituximab + TGR-1202
- DRUG Ublituximab + TGR-1202 + ibrutinib
- DRUG Ublituximab + TGR-1202 + bendamustine
Study Locations (6)
Alabama
- TG Therapeutics Investigational Trial Site - Huntsville
Arkansas
- TG Therapeutics Investigational Trial Site - Jonesboro
California
- TG Therapeutics Investigational Trial Site - Duarte
Georgia
- TG Therapeutics Investigational Trial Site - Atlanta
Nebraska
- TG Therapeutics Investigational Trial Site - Omaha
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2013-12-13 |
| Est. Completion | 2019-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006485
The ClinicalTrials.gov registry entry for NCT02006485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (12% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Ublituximab + TGR-1202 is the first listed.
NCT02006485 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT02006485 about?
NCT02006485 is a clinical study titled "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies". The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
What is the current status of trial NCT02006485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2013-12-13. Estimated completion is 2019-10.
What conditions does trial NCT02006485 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02006485?
The interventions under investigation include: Ublituximab + TGR-1202 (DRUG), Ublituximab + TGR-1202 + ibrutinib (DRUG), Ublituximab + TGR-1202 + bendamustine (DRUG).
Who is sponsoring clinical trial NCT02006485?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02006485 being conducted?
This trial has 6 study locations across Alabama, Arkansas, California, Georgia, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.